The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | The potential future role of KLN-1010, an in vivo CAR T-cell therapy, in R/R multiple myeloma
In this video, P. Joy Ho, MBBS, DPhil, FRACP, FRCPA, FFSc(RCPA), Royal Prince Alfred Hospital & University of Sydney, Sydney, Australia, discusses the future potential of KLN-1010, an off-the-shelf in vivo CAR-T, for relapsed/refractory (R/R) multiple myeloma (MM). Prof. Ho notes that the next steps will involve establishing the recommended Phase II dose of KLN-1010 and proceeding to Phase II studies, with the goal of making in vivo CAR-T a more affordable and accessible treatment option for patients. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So I think it’s important to remember that the inMMyCAR study is a Phase I first in human study. And while we are very gratified by the results with very high efficacy and very good tolerability, which probably explains why we are able to present it at a relatively early phase, we will look forward to establishing the recommended Phase II dose soon. And then with that, we’re likely to be able to proceed to Phase II and even Phase III studies...
So I think it’s important to remember that the inMMyCAR study is a Phase I first in human study. And while we are very gratified by the results with very high efficacy and very good tolerability, which probably explains why we are able to present it at a relatively early phase, we will look forward to establishing the recommended Phase II dose soon. And then with that, we’re likely to be able to proceed to Phase II and even Phase III studies. Overall, however, within relapsed/refractory myeloma, I think it gives the promise of a really important role for off-the-shelf therapy because it will assist many patients for whom CAR-T is really the answer, but they are unable to get to CAR-T because of their disease or the lack of bridging options and so forth. And in addition, in vivo CAR-T is likely to expand access also because the logistics are such that they will be economically much more affordable. That’s what we hope. And so more patients will be able to benefit from it.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
